Chronic Lymphocytic Leukemia | Proceedings from a live event held during the Society of Hematologic Oncology 2021 Annual Meeting

Featuring perspectives from Drs Jeff Sharman, Mitchell Smith and Philip Thompson, including the following topics: Treatment of CLL in 2021 Introduction (0:00) First-line therapy for a younger and fit patient with CLL (11:52) Case: A man in his mid-60s with IGHV-unmutated CLL — Mitchell R Smith, MD, PhD (16:20) Case: A man in his mid-30s with IGHV-unmutated CLL — Philip A Thompson, MD, BS (20:24) Case: A woman in her late 60s with IGHV-mutated, trisomy 12, TP53 wild-type CLL — Jeff Sharman, MD (25:11) First-line therapy for older and frail patients with CLL (26:55) Case: A man in his early 70s with IGHV-unmutated CLL — Dr Thompson (31:04) First-line therapy for patients with high-risk CLL (33:37) Choice of Bruton tyrosine kinase (BTK) inhibitor for the treatment of CLL (36:02) Prevention and management of COVID-19 in patients with CLL (43:21) Future Treatment of CLL Future role of BTK inhibitors combined with venetoclax in the management of CLL (48:33) Future role of pirtobrutinib (LOXO-305) in the management of CLL (52:22) Case: A woman in her late 60s with multiregimen-relapsed CLL — Dr Sharman (55:10) Case: A woman in her mid-50s with multiregimen-relapsed CLL — Dr Thompson (57:32) CME information and select publications